Inactive Instrument

Emerald Health Therapeutics

Equities

EMH

CA29102R1064

Emerald Health Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 29, 2022

Emerald Health Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was CAD 0.834 million compared to CAD 3.04 million a year ago. Net loss was CAD 1.86 million compared to CAD 13.96 million a year ago. Basic loss per share from continuing operations was CAD 0.01 compared to CAD 0.07 a year ago.
For the six months, revenue was CAD 2.75 million compared to CAD 5.3 million a year ago. Net loss was CAD 5.63 million compared to CAD 16.86 million a year ago. Basic loss per share from continuing operations was CAD 0.026 compared to CAD 0.08 a year ago.

Latest news about Emerald Health Therapeutics

C3 Souvenir Holding, Inc. completed the acquisition of Verdelite Sciences, Inc. from Emerald Health Therapeutics, Inc.	23-02-08	CI
C3 Souvenir Holding, Inc. entered into a share purchase agreement to acquire Verdelite Sciences, Inc. from Emerald Health Therapeutics, Inc. for CAD 12 million.	22-11-13	CI
Skye Bioscience, Inc. completed the acquisition of Emerald Health Therapeutics, Inc. from Emerald Health Sciences Inc. and others.	22-11-09	CI
Emerald Health Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-29	CI
Skye Bioscience Reports that CSE-listed Emerald Health Therapeutics Shareholders Voted in Favor of Plan of Arrangement	22-08-19	MT
Transcript : Emerald Health Therapeutics, Inc. - Shareholder/Analyst Call	22-08-19
Certain Emerald Health Shareholders Oppose Proposed Merger with Skye Biosciences	22-08-04	MT
Emerald Health Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-07-08	CI
Emerald Health Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-06-30	CI
Emerald Health Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	22-06-29	CI
Skye Bioscience, Inc. entered into term sheet to acquire Emerald Health Therapeutics, Inc. from Emerald Health Sciences Inc. and others for CAD 24.4 million.	22-05-10	CI
Emerald Health Therapeutics, Inc. Approves Board Appointments	21-12-31	CI
Transcript : Emerald Health Therapeutics, Inc. - Shareholder/Analyst Call	21-12-30
Emerald Health Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-29	CI
An unknown buyer agreed to acquire Recreational and Medical Cannabis Business of Emerald Health Therapeutics, Inc.	21-11-28	CI
Emerald Health Therapeutics, Inc. and HYTN Cannabis to Launch Cannabis Beverages in Canada	21-11-03	CI
Jenn Hepburn Steps Down as Chief Financial Officer of Emerald Health Therapeutics, Inc., effective October 15, 2021	21-09-10	CI
Transcript : Emerald Health Therapeutics, Inc., Q2 2021 Earnings Call, Aug 31, 2021	21-08-31
Emerald Health Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-29	CI
Emerald Health Therapeutics, Inc Appoints Nick Mosgrove as VP Sales & Marketing	21-08-10	CI
Emerald Health Therapeutics, Inc. Announces Resignation of Avtar Dhillon as Director and Executive Chairman of its Board of Directors	21-08-06	CI
Emerald Health Therapeutics, Inc. Launches Fuse™ Lifestyle Brand with Fast-Acting Cannabis-Infused Beverage	21-07-20	CI
Emerald Health Therapeutics : Tbd30's Manager Takes Stabilization Measures Following Stockholm Listing	21-07-06	MT
Emerald Health Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-30	CI
The Uplifers's PRIMA announced that it has received $9.2 million in funding from a group of investors	21-05-20	CI

Chart Emerald Health Therapeutics

Duration

Period

More charts

Company Profile

Emerald Health Therapeutics, Inc. is a Canada-based company, which is engaged in the business of production, distribution, and sale of cannabis products in Canada. The Company's segments include Cannabis and Other. It primarily operates in the Cannabis segment. It provides recreational, medical and wellness-oriented cannabis products. It offers products through brands, including SYNC Wellness, Fuse, whole-flower cannabis, Souvenir and Health Therapeutics. Its SYNC Wellness products include nanoemulsions and cannabis oils. Its Fuse product include nanoemulsion shots. Its whole-flower cannabis products consist of dried cannabis and pre-rolled cannabis. Its Souvenir product is dried flower, which is hang-dried and hand-packaged to optimize terpene profiles. Its Health Therapeutics offers medical products. Its subsidiaries include Emerald Health Therapeutics Canada Inc., Emerald Health Naturals Inc., Avalite Sciences Inc., Verdelite Sciences Inc., and Verdelite Property Holdings Inc.

Sector

More about the company